{"artifact":{"id":"experiment_proposal-8c48ed63-08d9-40ff-b2d1-3a27b1c0a6ac","artifact_type":"experiment_proposal","entity_ids":"[\"Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction\"]","title":"Experiment Proposal (crux): Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction — Composite index performance superiority over individual biomarkers not demonstra","quality_score":0.5,"created_by":"crux_generator:skeptic","provenance_chain":"[]","content_hash":"55aca63f300f55f7548805c6f0b9e4ae9d881a2d1adf0a22e6e60a2ed1dbc8e0","metadata":{"aims":["Determine whether a multi-biomarker composite index (MBI) outperforms individual biomarkers for treatment response prediction in Alzheimer's disease","Determine whether the MBI outperforms amyloid PET (SUVR) in predicting treatment response to anti-amyloid therapies","Establish the minimum necessary biomarker panel composition required for predictive parity with amyloid PET"],"source":"debate_crux","hypotheses":["H1: The multi-biomarker composite index demonstrates superior receiver operating characteristic (ROC) area under curve (AUC) compared to any single biomarker (Aβ42/40 ratio, p-tau217, p-tau181, NfL, GFAP) for treatment response classification (null: no significant AUC difference)","H2: The MBI demonstrates non-inferiority to amyloid PET SUVR for treatment response prediction (AUC difference margin < 0.1), with potential superiority to be tested directionally","H3: A reduced three-marker panel (Aβ42/40 + p-tau217 + GFAP) achieves ≥90% of the full MBI predictive performance, suggesting parsimonious alternatives"],"debate_type":"hypothesis_debate","est_cost_usd":48000.0,"persona_used":"Skeptic","crux_question":"Composite index performance superiority over individual biomarkers not demonstrated","key_weaknesses":["Central claim of 'surpassing' amyloid PET is empirically untested with no head-to-head comparative data provided","The hypothesis describes a biomarker strategy, not a druggable target—biomarkers cannot be directly modulated","Reference standard problem: 'treatment response' lacks operational definition for validation purposes","Composite index performance superiority over individual biomarkers not demonstrated","Lacks primary data from prospective clinical trial cohorts comparing composite performance to PET-derived SUVR"],"_schema_version":1,"hypothesis_title":"Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction","protocol_summary":"Phase 1 - Retrospective Validation: Retrieve archived plasma samples from ADNI, TRIAD, and EMIF-AD cohorts (n=800 total; 400 treatment-responders defined by 12-month cognitive stabilization or improvement on CDRsb/ADAS-Cog13, 400 non-responders matched by age/sex/baseline severity). Measure biomarkers in duplicate using Lumipulse (Fujirebio) for Aβ42/40, p-tau181, p-tau217, and Simoa for NfL/GFAP. Calculate MBI using pre-specified algorithm: MBI = 0.35×(Aβ42/40 z-score) + 0.25×(p-tau217 z-score) + 0.20×(p-tau181 z-score) + 0.10×(NfL z-score) + 0.10×(GFAP z-score). Acquire amyloid PET SUVR values (Centiloid conversion) from existing datasets. Phase 2 - Head-to-Head Classification: Conduct matched cross-validation (5-fold, 10-repeat) comparing AUC for response prediction: MBI vs each individual biomarker vs amyloid PET SUVR alone. Calculate Delong test for AUC comparison with Bonferroni correction. Phase 3 - Non-Inferiority Test: Apply pre-specified non-inferiority margin (δ = 0.10). If lower bound of 95% CI for AUC difference (MBI - PET) exceeds -δ, non-inferiority established. Phase 4 - Minimal Panel Analysis: Recursively eliminate markers to identify reduced panel maintaining ≥90% full MBI performance. All biomarker assays performed in ISO 17025 accredited facility with blinded clinical outcome assessment.","debate_session_id":"sess_hypdebate_h_45d23b07_20260426_165108","synthesis_summary":"The hypothesis proposes a composite biomarker approach integrating amyloid (Aβ42/Aβ40 ratio, p-tau217), tau (p-tau181, p-tau217), and neurodegeneration markers to predict treatment response in Alzheimer's disease with superior accuracy to amyloid PET. While the mechanistic rationale is scientifically sound and individual biomarkers are well-validated, the central comparative superiority claim remains empirically untested. Critically, this represents a biomarker-based predictive strategy rather t","est_duration_weeks":16.0,"dataset_dependencies":["TRIAD (Translational Biomarkers in Aging and Dementia) cohort - baseline and longitudinal samples","EMIF-AD MBD (European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery) cohort","ADNI (Alzheimer's Disease Neuroimaging Initiative) - plasma biomarkers + amyloid PET baseline","DIAN (Dominantly Inherited Alzheimer Network) - longitudinal plasma + PET data","Treatment trial archives: BAN2401 (CLARITY-AD), TRAILBLAZER-ALZ (donanemab), TRAILBLAZER-ALZ 2 - access to archived plasma samples for biomarker measurement"],"falsification_criteria":"H1 falsified: No significant AUC difference between best single biomarker (predicted: p-tau217) and MBI (DeLong test p > 0.05 after correction), indicating composite provides no additional predictive value beyond validated single markers. H2 falsified: Lower 95% CI bound for AUC(MBI) - AUC(PET) falls below -0.10 (non-inferiority margin), establishing MBI is inferior to amyloid PET for treatment response. H3 falsified: Reduced panel retains <90% of full MBI performance, indicating all five markers are necessary and redundancy does not exist. Grand falsification: Even the full MBI fails to exceed chance-level prediction (AUC CI < 0.55), indicating biomarkers have no predictive utility for treatment response in this cohort.","predicted_observations":"If the hypothesis is true: MBI will show statistically significant AUC improvement over individual biomarkers (estimated ΔAUC 0.08-0.12) and meet non-inferiority threshold against amyloid PET (potentially exceeding PET AUC by 0.05-0.08 given mechanistically broader pathology capture). Reduced three-marker panel will retain ≥90% predictive power, indicating robust signal across mechanistically distinct pathways."},"created_at":"2026-04-27T01:52:37.363844-07:00","updated_at":"2026-04-27T01:52:37.363844-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":null,"citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"ddfe89ea-a823-49a0-9117-87422f6ffcab","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"crux_generator:skeptic"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[{"source_artifact_id":"open_question-cae3f33d-c521-41eb-a129-de88719231be","link_type":"partial_answer_for","strength":0.82,"evidence":"{\"confidence\": 0.82, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-da1e9982-ec8c-4617-b91d-e74888adb4e4","link_type":"partial_answer_for","strength":0.55,"evidence":"{\"confidence\": 0.55, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-a2a38885-4a88-4d62-a4ae-068ab9fbb347","link_type":"partial_answer_for","strength":0.74,"evidence":"{\"confidence\": 0.74, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-557e39f7-3cb6-4da9-bad0-5e8194282520","link_type":"bears_on_question","strength":0.52,"evidence":"{\"confidence\": 0.52, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-642754e6-5f66-4f8a-a2c6-efaa408bca05","link_type":"partial_answer_for","strength":0.72,"evidence":"{\"confidence\": 0.72, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"},{"source_artifact_id":"open_question-8036ec14-2b4a-45ca-bb70-74b119880199","link_type":"discriminating_experiment","strength":0.82,"evidence":"{\"confidence\": 0.82, \"judge_persona\": \"domain-expert\", \"model\": \"all-MiniLM-L6-v2\"}"}],"current_artifact_id":"experiment_proposal-8c48ed63-08d9-40ff-b2d1-3a27b1c0a6ac","is_canonical":true,"supersede_chain":["experiment_proposal-8c48ed63-08d9-40ff-b2d1-3a27b1c0a6ac"]}